齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性对比分析

Analysis of Ziprasidone and Risperidone in the Treatment of Schizophrenia Clinical Curative Effect and Safety Comparison

目的对比分析齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性。方法收集2014年9月~2015年8月来我院进行治疗的精神分裂症患者共94例,随机分为两组,对照组和研究组各47例,研究组用齐拉西酮治疗,对照组用利培酮治疗,比较两组治疗前及治疗后8周的PANSS总分、临床疗效。结果治疗后8周两组PANSS总分与治疗前比较均出现明显降低,研究组降低的程度高于对照组,两组差异有统计学意义（P〈0.05）。对照组总有效率为78.72%,研究组为93.62%,两组总有效率比较差异有统计学意义（P〈0.05）。两组不良反应发生率差异无统计学意义（P〉0.05）。结论齐拉西酮治疗精神分裂症的临床效果显著,可有效改善患者的临床症状,疗效优于利培酮治疗,且有较高的安全性。

Objective To compare the clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods 94 patients with schizophrenia were selected from September 2014 to August 2015 to our hospital for treatment, they were randomly divided into two groups, there were 47 cases in the control group and the study groups, the study group treated with ziprasidone, the control group treated with risperidone, PANSS total score before and after 8 weeks treatment, the clinical efficacy of two group were compared. Results PANSS total score of two groups after 8 weeks treatment were significant lower than before treatment, degree of reduction in the study group was significantly higher than the control group, the difference was statistically significant （P〈0.05）. The total effective rate of the control group was 78.72%, the study group was 93.62%, two sets of the overall efficiency of the difference was statistically significant （P〈0105）. There were no significant difference on the adverse reaction rates between the two groups （P〉0.05）. Conclusion Ziprasidone treatment of schizophrenia significant clinical effect, which can effectively improve the clinical symptoms, significantly better than risperidone, the security is higher.